Yahoo Finance Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
EVP Research & Development Fady Malik executed a sale of 7,300 shares of Cytokinetics Inc (NASDAQ:CYTK) on July 9, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 131,004 shares of the company.
Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is dedicated to innovations in muscle biology and related mechanisms that can lead to novel treatments for people suffering from severe diseases.
Over the past year, Fady Malik has sold a total of 131,323 shares of Cytokinetics Inc and has not purchased any shares. The insider transaction history for Cytokinetics Inc shows a total of 42 insider sells and no insider buys over the past year.
Shares of Cytokinetics Inc were trading at $55.9 on the day of the insider's recent transaction. The company has a market cap of $6.43 billion.
According to the GF Value, the intrinsic value estimate for Cytokinetics Inc is $3.66, leading to a price-to-GF-Value ratio of 15.27, indicating that the stock is Significantly Overvalued. The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This sale by the insider could be of interest to current and potential investors, providing insight into insider confidence and stock valuation based on recent market trends and company performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
